214 related articles for article (PubMed ID: 21617923)
21. Fludarabine combined with cyclophosphamid is highly effective in the treatment of chronic lymphocytic leukemia.
Tóthová E; Kafková A; Fricová M; Guman T; Stecová N
Neoplasma; 2003; 50(6):433-7. PubMed ID: 14689065
[TBL] [Abstract][Full Text] [Related]
22. Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997.
Flinn IW; Neuberg DS; Grever MR; Dewald GW; Bennett JM; Paietta EM; Hussein MA; Appelbaum FR; Larson RA; Moore DF; Tallman MS
J Clin Oncol; 2007 Mar; 25(7):793-8. PubMed ID: 17283364
[TBL] [Abstract][Full Text] [Related]
23. Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia.
O'Brien S; Moore JO; Boyd TE; Larratt LM; Skotnicki A; Koziner B; Chanan-Khan AA; Seymour JF; Bociek RG; Pavletic S; Rai KR
J Clin Oncol; 2007 Mar; 25(9):1114-20. PubMed ID: 17296974
[TBL] [Abstract][Full Text] [Related]
24. Bendamustine in chronic lymphocytic leukemia: outcome according to different clinical and biological prognostic factors in the everyday clinical practice.
Zaja F; Mian M; Volpetti S; Visco C; Sissa C; Nichele I; Castelli M; Ambrosetti A; Puglisi S; Fanin R; Cortelazzo S; Pizzolo G; Trentin L; Rodeghiero F; Paolini R; Vivaldi P; Sancetta R; Isola M; Semenzato G
Am J Hematol; 2013 Nov; 88(11):955-60. PubMed ID: 23861234
[TBL] [Abstract][Full Text] [Related]
25. Comparison between oral and intravenous fludarabine plus cyclophosphamide regime as front-line therapy in patients affected by chronic lymphocytic leukaemia: influence of biological parameters on the clinical outcome.
Laurenti L; De Padua L; Tarnani M; Piccirillo N; Falcucci P; D'Arena G; Innocenti I; Marietti S; Efremov DG; Chiusolo P; Zini G; Sora' F; Sica S; Leone G
Ann Hematol; 2011 Jan; 90(1):59-65. PubMed ID: 20625902
[TBL] [Abstract][Full Text] [Related]
26. Immune recovery after fludarabine-cyclophosphamide-rituximab treatment in B-chronic lymphocytic leukemia: implication for maintenance immunotherapy.
Ysebaert L; Gross E; Kühlein E; Blanc A; Corre J; Fournié JJ; Laurent G; Quillet-Mary A
Leukemia; 2010 Jul; 24(7):1310-6. PubMed ID: 20463751
[TBL] [Abstract][Full Text] [Related]
27. VNCOP-B plus rituximab therapy in elderly patients with aggressive B-cell non-Hodgkin lymphoma: a multicenter experience.
Ishii K; Urase F; Nagare Y; Kimura H; Manabe M; Yagi T; Teshima H; Hayashi K; Shibano M; Tsukaguchi M; Katsurada T; Mugitani A; Kitayama H; Nomura S
Arch Gerontol Geriatr; 2010; 51(2):209-15. PubMed ID: 19926148
[TBL] [Abstract][Full Text] [Related]
28. [Basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) are elevated in peripheral blood plasma of patients with chronic lymphocytic leukemia and decrease after intensive fludarabine-based treatment].
Smolej L; Andrýs C; Krejsek J; Belada DZ; Zák P; Siroký O; Malý J
Vnitr Lek; 2007 Nov; 53(11):1171-6. PubMed ID: 18277626
[TBL] [Abstract][Full Text] [Related]
29. Immune anaemias in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab--incidence and predictors.
Borthakur G; O'Brien S; Wierda WG; Thomas DA; Cortes JE; Giles FJ; Kantarjian HM; Lerner S; Keating MJ
Br J Haematol; 2007 Mar; 136(6):800-5. PubMed ID: 17341265
[TBL] [Abstract][Full Text] [Related]
30. Rituximab, fludarabine, cyclophosphamide, and mitoxantrone: a new, highly active chemoimmunotherapy regimen for chronic lymphocytic leukemia.
Bosch F; Abrisqueta P; Villamor N; Terol MJ; González-Barca E; Ferra C; González Diaz M; Abella E; Delgado J; Carbonell F; García Marco JA; Escoda L; Ferrer S; Monzó E; González Y; Estany C; Jarque I; Salamero O; Muntañola A; Montserrat E
J Clin Oncol; 2009 Sep; 27(27):4578-84. PubMed ID: 19704063
[TBL] [Abstract][Full Text] [Related]
31. A randomized, open-label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab versus fludarabine, cyclophosphamide and rituximab alone in subjects with relapsed chronic lymphocytic leukaemia.
Awan FT; Hillmen P; Hellmann A; Robak T; Hughes SG; Trone D; Shannon M; Flinn IW; Byrd JC;
Br J Haematol; 2014 Nov; 167(4):466-77. PubMed ID: 25130401
[TBL] [Abstract][Full Text] [Related]
32. Fludarabine, cyclophosphamide and rituximab plus granulocyte macrophage colony-stimulating factor as frontline treatment for patients with chronic lymphocytic leukemia.
Strati P; Ferrajoli A; Lerner S; O'Brien S; Wierda W; Keating MJ; Faderl S
Leuk Lymphoma; 2014 Apr; 55(4):828-33. PubMed ID: 23808813
[TBL] [Abstract][Full Text] [Related]
33. Myelosuppression after frontline fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: analysis of persistent and new-onset cytopenia.
Strati P; Wierda W; Burger J; Ferrajoli A; Tam C; Lerner S; Keating MJ; O'Brien S
Cancer; 2013 Nov; 119(21):3805-11. PubMed ID: 23943357
[TBL] [Abstract][Full Text] [Related]
34. Single-agent rituximab in treatment-refractory or poor prognosis patients with chronic lymphocytic leukemia.
Wiernik PH; Adiga GU
Curr Med Res Opin; 2011 Oct; 27(10):1987-93. PubMed ID: 21905969
[TBL] [Abstract][Full Text] [Related]
35. [Prognostic significance of immunoglobulin variable region gene mutations in B-CLL patients treated with combination therapy fludarabine plus cyclophosphamide].
Nikitin EA; Stadnik EA; Lorie IuIu; Biderman BV; Tsyba NN; Salogub GN; Kolosheĭnova TI; Kolosova LIu; Risinskaia NA; Zaritskiĭ IuA; Kovaleva LG; Sudarikov AB
Ter Arkh; 2007; 79(7):66-70. PubMed ID: 17802794
[TBL] [Abstract][Full Text] [Related]
36. [Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab].
Tsukasaki K
Nihon Rinsho; 2015 Feb; 73 Suppl 2():632-5. PubMed ID: 25831837
[No Abstract] [Full Text] [Related]
37. Pentostatin (Nipent) and chlorambucil with granulocyte-macrophage colony-stimulating factor support for patients with previously untreated, treated, and fludarabine-refractory B-cell chronic lymphocytic leukemia.
Waselenko JK; Grever MR; Beer M; Lucas MA; Byrd JC
Semin Oncol; 2000 Apr; 27(2 Suppl 5):44-51. PubMed ID: 10877052
[TBL] [Abstract][Full Text] [Related]
38. Early and late infectious consequences of adding rituximab to fludarabine and cyclophosphamide in patients with indolent lymphoid malignancies.
Tam C; Seymour JF; Brown M; Campbell P; Scarlett J; Underhill C; Ritchie D; Bond R; Grigg AP
Haematologica; 2005 May; 90(5):700-2. PubMed ID: 15921393
[TBL] [Abstract][Full Text] [Related]
39. Low-dose fludarabine and cyclophosphamide combined with standard dose rituximab (LD-FCR) is an effective and safe regimen for elderly untreated patients with chronic lymphocytic leukemia: The Israeli CLL study group experience.
Herishanu Y; Tadmor T; Braester A; Bairey O; Aviv A; Rahimi-Levene N; Fineman R; Levi I; Yuklea M; Ruchlemer R; Shvidel L; Polliack A
Hematol Oncol; 2019 Apr; 37(2):185-192. PubMed ID: 30756414
[TBL] [Abstract][Full Text] [Related]
40. Severe infusion-related reactions are uncommon in rituximab-treated CLL patients in clinical practice: results from a Swedish national observational study.
Norin S; Björkstrand B; Rommel F; Timberg L; Andersson PO; Häggström J; Aldrin A; Hansson L
Leuk Res; 2015 Jan; 39(1):33-7. PubMed ID: 25499233
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
